Clinical Rheumatology

, Volume 9, Supplement 1, pp 100–110 | Cite as

Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease

  • R. Smeenk
  • K. Brinkman
  • H. Van Den Brink
  • R. -M. Termaat
  • J. Berden
  • H. Nossent
  • T. Swaak


In this paper an overview of the present knowledge on antibodies against DNA will be presented. Diagnostic, prognostic and pathogenic aspects of anti-DNA will be highlighted. Detection of antibodies to DNA in the circulation of a patient by an assay selective for high avidity anti-DNA is highly diagnostic for SLE. Anti-DNA of low avidity occurs in rheumatic diseases other than SLE as well, making detection of such antibodies of less diagnostic value. Furthermore, data will be presented that show that the anti-DNA ELISA in its present form is not suited as a diagnostic tool. Not only disease features of SLE vary from patient to patient, anti-DNA avidity does so too. A relationship between anti-DNA avidity and clinical features can be found: high avidity anti-DNA is more abundant in patients with nephritis, low avidity anti-DNA in patients with CNS involvement. Prognostically, a steady increase of the level of high avidity anti-DNA generally heralds an upcoming exacerbation in a patient. Furthermore, 85% of the patients who do not have SLE at the time (high avidity) anti-DNA is detected in their serum, will develop the disease within the next few years. It is noteworthy, that patients with only low avidity anti-DNA in their circulation develop a more mild form of SLE; the (low) avidity of their anti-DNA seldomly increases during the course of their disease. The relevance of anti-DNA to the pathogenesis of SLE still is a matter of debate. On the one hand, the association of parameters of anti-DNA that determine the size of the complexes formed with DNA is in favour of the classical hypothesis, which states that SLE is primarily an immune complex disease. On the other hand, recent data on crossreactions of anti-DNA with phospholipids, glycosaminoglycans and other (polynegative) structures plead for a role of such crossreactivities in the pathogenesis of SLE.

Key words

Anti-DNA ELISA RIA Crithidia Luciliae Farr Assay PEG Assay SLE Diagnosis Pathogenesis Crossreactivity Longitudinal study 



antinuclear antibodies


central nervous system


doublestranded DNA


enzymelinked immunosorbent assay


indirect immunofluorescence technique


polyethylene glycol


radio immunoassay


systemic lupus erythematosus


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hughes, G.R.V. Connective tissue diseases. Oxford, Blackwell Scientific Publications, 1977, 3–65.Google Scholar
  2. 2.
    Lahita, R.G. Systemic Lupus Erythematosus. New York, John Wiley & sons, 1987, 1–1000.Google Scholar
  3. 3.
    Stollar, B.D. Nucleic acid antigens. In: The antigens, vol. I. Editor: Sela, M., New York, Academic Press, 1973, 1–85.Google Scholar
  4. 4.
    Smeenk, R.J.T., Westgeest, A.A.A., Swaak, A.J.G. Antinuclear antibody determination: the present state of diagnostic and clinical relevance. Scand J Rheumatol 1985, 56 (suppl), 78–92.Google Scholar
  5. 5.
    Roder, J.C., Bell, D.A., Singhal, S.K. Regulation of the autoimmune plaqueforming cell response to singlestranded DNA (ssDNA) in vitro. J Immunol 1978, 121, 38–45.Google Scholar
  6. 6.
    Fournié, G.J., Lambert, P.H., Miescher, P.A. Release of DNA in the circulating blood and induction of anti-DNA antibodies after injection of bacterial lipopolysaccharides. J Exp Med 1974, 140, 1189–1196.Google Scholar
  7. 7.
    Izui, S., Zaldivar, N.M., Scher, I., Lambert, P.H. Mechanism for the induction of anti-DNA antibodies by bacterial lipopolysaccharides in mice. I. Anti-DNA induction by LPS without significant release of DNA in the circulating blood. J Immunol 1977, 119, 2151–2157.Google Scholar
  8. 8.
    Dighiero, G., Lymberi, P., Guilbert, B., Ternynck, T., Avrameas, S. Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann NY Acad Sci 1986, 475, 135–145.Google Scholar
  9. 9.
    Ternynck, T., Avrameas, S. Murine natural monoclonal autoantibodies: a study of their polyspecificity and their affinities. Immunol Rev 1986, 94, 99–112.Google Scholar
  10. 10.
    Cairns, E., Block, J., Bell, D.A. Anti-DNA autoantibody producing hybridomas of normal human lymphoid cell origin. J Clin Invest 1984, 74, 880–889.Google Scholar
  11. 11.
    Rolink, A.G., Radaszkiewicz, T., Melchers, F. The autoantigenbinding B cell repertoires of normal and of chronically graftversus-host-diseased mice. J Exp Med 1987, 165, 1675–1687.Google Scholar
  12. 12.
    Swaak, A.J.G., Smeenk, R. Clinical differences between SLE patients in relation to the avidity of their anti-dsDNA. In: Protides of the biological fluids. 33th ed., Editor: Peeters, H., London, Pergamon Press 1985, 317–320.Google Scholar
  13. 13.
    Tan, E.M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982, 33, 167–240.Google Scholar
  14. 14.
    Klinman, D.M., Steinberg, A.D. Autoimmunity. In: Systemic Lupus Erythematosus. Ed: Lahita, R.G., New York, John Wiley & Sons, 1987, 7–14.Google Scholar
  15. 15.
    Tan, E.M., Cohen, A.S., Fries, J.S., Masi, A.T., McShane, D.J., Rothfield, N.F., Green Schaller, J., Talal, N., Winchester, R.J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25, 1271–1277.Google Scholar
  16. 16.
    Smeenk, R. A comparison of four different anti-DNA assays. In: Immunoassay Technology, volume 2. Editor: Pal, S.B., Berlin-New York, Walter de Gruyter, 1986, 145–166.Google Scholar
  17. 17.
    Smeenk, R., van der Lelij, G., Aarden, L.A. Measurements of low avidity anti-dsDNA by theCrithidia luciliae test and the PEG-assay. Clin Exp Immunol 1982, 50, 603–610.Google Scholar
  18. 18.
    Smeenk, R., Aarden, L.A. The use of polyethylene glycol precipitation to detect low avidity anti-DNA antibodies in Systemic Lupus Erythematosus. J Immunol Methods 1980, 39, 165–180.Google Scholar
  19. 19.
    Nossent, J.C., Huysen, V., Smeenk, R.J.T., Swaak, A.J.G. Low avidity antibodies to dsDNA as a diagnostic tool. Ann Rheum Dis 1989, 48, 748–752.Google Scholar
  20. 20.
    Swaak, A.J.G., Aarden, L.A., Statius van Eps, L.W., Feltkamp, T.E.W. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979, 22, 226–235.Google Scholar
  21. 21.
    Swaak, A.J.G., Groenwold, J., Aarden, L.A., Feltkamp, T.E.W. Detection of anti-dsDNA as a diagnostic tool. Ann Rheum Dis 1981, 40, 45–49.Google Scholar
  22. 22.
    Swaak, A.J.G., Groenwold, J., Aarden, L.A., Statius van Eps, L.W., Feltkamp, T.E.W. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis 1982, 41, 388–395.Google Scholar
  23. 23.
    Swaak, A.J.G., Groenwold, J., Bronsveld, W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986, 45, 359–366.Google Scholar
  24. 24.
    Swaak, A.J.G., Smeenk, R. Detection of anti-ds-DNA as a diagnostic tool: a prospective study in 441 non systemic lupus erythematosus (SLE) patients with anti-dsDNA antibody (andi-dsDNA). Ann Rheum Dis 1985, 44, 245–251.Google Scholar
  25. 25.
    Nossent, J.C., Huysen, V., Smeenk, R.J.T., Swaak, A.J.G. Low avidity antibodies to dsDNA in SLE: a longitudinal study on their clinical significance. Ann Rheum Dis 1989, 48, 677–682.Google Scholar
  26. 26.
    Koffler, D., Agnello, V., Thoburn, R., Kunkel, H.G. SLE, prototype of immune complex nephritis in man. J Exp Med 1971, 134, 169S-179S.Google Scholar
  27. 27.
    Smeenk, R., van Rooyen, A., Swaak, A.J.G. Dissociation studies of DNA/anti-DNA complexes in relation to anti-DNA avidity. J Immunol Methods 1988, 109, 27–35.Google Scholar
  28. 28.
    De Groot, E.R., Lamers, M.C., Aarden, L.A., Smeenk, R.J.T., van Oss, C.J. Dissociation of DNA/anti-DNA complexes at high pH. Immunol Comm 1980, 9, 515–528.Google Scholar
  29. 29.
    Smeenk, R.J.T., Aarden, L.A., van Oss, C.J. Comparison between dissociation and inhibition of association of DNA/anti-dsDNA complexes. Immunol Comm 1983, 12, 177–188.Google Scholar
  30. 30.
    Van Oss, C.J., Smeenk, R.J.T., Aarden, L.A. Inhibition of association versus dissociation of high avidity DNA/anti-DNA complexes: possible involvement of secondary hydrogen bonds. Immunol Invest 1985, 14, 245–253.Google Scholar
  31. 31.
    Eilat, D. Cross-reactions of anti-DNA antibodies and the central dogma of lupus nephritis. Immunol Today 1986, 6–4, 123–127.Google Scholar
  32. 32.
    Steinman, C.R. Circulating DNA in SLE. Isolation and characterization. J Clin Invest 1984, 73, 832–838.Google Scholar
  33. 33.
    McCoubrey-Hoyer, A., Okarma, T.B., Holman, H.R. Partial purification and characterization of plasma DNA and its relation to disease activity in systemic lupus erythematosus. Am J Med 1984, 77, 23–34.Google Scholar
  34. 34.
    Emlen, W., Mannik, M. Effect of DNA size and strandedness on the in vitro clearance and organ localization of DNA. Clin Exp Immunol 1984, 56, 185–192.Google Scholar
  35. 35.
    Emlen, W., Mannik, M. Clearance of circulating DNA/anti-DNA immune complexes in mice. J Exp Med 1982, 155, 1210–1217.Google Scholar
  36. 36.
    Koffler, D., Schur, P.M., Kunkel, H.G. Immunological studies concerning the nephritis of SLE. J Exp Med 1967, 126, 607–613.Google Scholar
  37. 37.
    Ebling, F.M., Hahn, B.H. Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus. Arthritis Rheum 1980, 23, 392–403.Google Scholar
  38. 38.
    Hahn, B.H. Characteristics of pathogenic subpopultions of antibodies to DNA. Arthritis Rheum 1982, 25, 747–756.Google Scholar
  39. 39.
    Dang, H., Harbeck, R.J. The in-vivo and in-vitro glomerular deposition of isolated anti-dsDNA antibodies in NZB/W mice. Clin Immunol Immunopathol 1984, 30, 265–273.Google Scholar
  40. 40.
    Faaber, P., Capel, P.J.A., Rijke, G.P.M., Vierwinden, G., Van de Putte, L.B.A., Koene, R.A.P. Crossreactivity of anti-DNA antibodies with proteoglycans. Clin Exp Immunol 1984, 55, 502–510.Google Scholar
  41. 41.
    Faaber, P., Rijke, G.P.M., Van de Putte, L.B.A., Capel, P.J.A., Berden, J.H.M. Crossreactivity of human and murine anti-DNA antibodies with heparan sulphate: the major glycosaminoglycan in glomerular basement membrane. J Clin Invest 1986, 77, 1824–1830.Google Scholar
  42. 42.
    Lafer, E.M., Rauch, J., Andrzejewski, C. Jr., Mudd, D., Furie, B., Schwartz, R.S., Stollar, D.B. Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J Exp Med 1981, 153, 897–909.Google Scholar
  43. 43.
    Shoenfeld, Y., Rauch, J., Massicotte, M., Stollar, B.D., Schwartz, R.S. Polyspecificity of monoclonal lupus autoantibodies produced by human-human hybridomas. N Engl J Med 1983, 308, 414–420.Google Scholar
  44. 44.
    Faaber, P., Rijke, G.P.M., Smeenk, R.J.T., Capel, P.J.A., Van de Putte, L.B.A., Berden, J.H.M. Crossreactivity of anti-DNA antibodies. A new clue for the pathogenesis of SLE?. In: Protides of the biological fluids. 33th ed., Editor: Peeters, H., London, Pergamon Press 1985, 405–408.Google Scholar
  45. 45.
    Brinkman, K., Termaat, R., de Jong, J., Van den Brink, H., Berden, J., Smeenk, R. Crossreactive binding paterns of monochonal antibodies to DNA are often caused by DNA/anti-DNA immune complexes. Res Immunol 1989, 140, 595–612.Google Scholar
  46. 46.
    Smeenk, R.J.T., Lucassen, W.A.M., Swaak, A.J.G. Is anticardiolipin activity a crossreaction of anti-DNA or a separate entity?. Arthritis Rheum 1987, 30, 607–617.Google Scholar
  47. 47.
    Beaulieu, A., Quismorio, F.K., Friou, G. Ig antibodies to dsDNA in SLE. Independent variation of complement-fixing and total antibody content. Arthritis Rheum 1979, 22, 565–570.Google Scholar
  48. 48.
    Ballou, S.P., Kushner, I. Immunochemical characteristics of antibodies to DNA in patients with active SLE. Clin Exp Immunol 1979, 37, 58–64.Google Scholar
  49. 49.
    Herrera Ezparza, R., Swaak, A.J.G., Aarden, L.A., Smeenk, R. Complement-fixing antibodies to dsDNA detected by immunofluorescence technique onCrithidia luciliae. A critical appraisal. J Rheumatol 1985, 12, 1109–1117.Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • R. Smeenk
    • 1
  • K. Brinkman
    • 1
  • H. Van Den Brink
    • 1
  • R. -M. Termaat
    • 1
    • 2
  • J. Berden
    • 1
    • 2
  • H. Nossent
    • 1
    • 3
  • T. Swaak
    • 1
    • 3
  1. 1.Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical ImmunologyUniversity of AmsterdamThe Netherlands
  2. 2.Department of NephrologyUniversity Hospital, University of NijmegenThe Netherlands
  3. 3.Department of RheumatologyDr Daniel Den Hoed ClinicRotterdamThe Netherlands

Personalised recommendations